| 摘要: |
| 目的:探讨化疗联合或不联合八珍汤加减治疗小细胞肺癌(SCLC)的有效性、安全性。方法:选取2020年1月—2021年6月河北中医学院附属沧州中西医结合医院收治的SCLC患者120例，按随机数字表法分两组，对照组(n=60)予EP化疗方案(依托泊苷+顺铂)，研究组(n=60)在对照组基础上联合八珍汤加减。对比两组疗效、CD细胞、生活质量、不良反应。结果:研究组客观缓解率(ORR)高于对照组(P＜0.05)。治疗后，对照组CD3+、CD4+、CD4+/CD8+均低于治疗前(P＜0.05)，CD8+高于治疗前(P＜0.05)，研究组CD3+、CD4+、CD4+/CD8+均高于治疗前(P＜0.05)，CD8+低于治疗前(P＜0.05)，且治疗后研究组CD3+、CD4+、CD4+/CD8+均高于对照组(P＜0.05)，CD8+低于对照组(P＜0.05)。治疗后，两组EORTC-QLQ-C30量表各维度得分均高于治疗前(P＜0.05)，且治疗后研究组EORTC-QLQ-C30量表各维度得分均高于对照组(P＜0.05)。研究组各不良反应的总发生率均低于对照组(P＜0.05)。结论:八珍汤加减联合化疗能提高SCLC患者疗效，改善患者免疫功能与生活质量，减轻化疗所致不良反应。 |
| 关键词: 八珍汤加减 化疗 小细胞肺癌 不良反应 |
| DOI：10.3969/j.issn.1007-6948.2023.03.002 |
| 投稿时间：2023-09-28 |
| 基金项目:河北省中医药管理局课题(2017297) |
|
| Clinical observation on treatment of small cell lung cancer with chemotherapy combined with modified Bazhen decoction |
| WANGZhen-qiang,CHENJing-jing,WANGHong-liang |
|
| Abstract: |
| Objective To explore the effectiveness and safety of chemotherapy combined with or without modified Bazhen decoction in the treatment of small cell lung cancer (SCLC). Methods From January 2020 to June 2021, 120 SCLC patients admitted to Cangzhou integrated traditional Chinese and Western Medicine Hospital Affiliated to Hebei College of traditional Chinese medicine were collected and separated into two groups using the random number table method. The control group (n=60) was given EP chemotherapy (etoposide+cisplatin), and the study group (n=60) was combined with modified Bazhen decoction on the basis of the control group. The efficacy, CD cells, quality of life and adverse reactions were compared between the two groups. Results The objective response rate (ORR) of the study group was higher than that of the control group (P<0.05). After treatment, the control group had lower CD3+, CD4+ and CD4+/CD8+ than before treatment (P<0.05), and higher CD8+ than before treatment (P<0.05), the study group had higher CD3+, CD4+ and CD4+/CD8+ than before treatment (P<0.05), and lower CD8+ than before treatment (P<0.05). After treatment, the study group had higher CD3+, CD4+, CD4+/CD8+ than the control group (P<0.05), and lower CD8+ than the control group (P<0.05). After treatment, the scores of all dimensions of the EORTC-QLQ-C30 scale in the two groups were higher than those before treatment (P<0.05). The scores of all dimensions of the EORTC-QLQ-C30 scale in the study group were higher than those in the control group after treatment (P<0.05). The study group had lower total incidence of adverse reactions than the control group (P<0.05). Conclusion Modified Bazhen decoction combined with chemotherapy can improve the curative effect of SCLC patients, improve the immune function and quality of life of patients, and reduce the adverse reactions caused by chemotherapy. |
| Key words: Bazhen decoction chemotherapy small cell lung cancer adverse reactions |
